Importer of Controlled Substances; Notice of Application GE Healthcare, 36594-36595 [2013-14456]
Download as PDF
<![CDATA[
36594
Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Hydromorphone (9150) ...............................................................................................................................................................................
Diphenoxylate (9170) ..................................................................................................................................................................................
Ecgonine (9180) ..........................................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Levomethorphan (9210) ..............................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Isomethadone (9226) ..................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Meperidine intermediate-B (9233) ...............................................................................................................................................................
Metazocine (9240) .......................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Metopon (9260) ...........................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Dihydroetorphine (9334) ..............................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
Phenazocine (9715) ....................................................................................................................................................................................
Piminodine (9730) .......................................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Racemorphan (9733) ...................................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Carfentanil (9743) ........................................................................................................................................................................................
Tapentadol (9780) .......................................................................................................................................................................................
Bezitramide (9800) ......................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I and II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C. 952
(a)(2)(B) may, in the circumstances set
forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 18, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
VerDate Mar<15>2010
16:52 Jun 17, 2013
Jkt 229001
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–14446 Filed 6–17–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application GE Healthcare
Pursuant to Title 21, Code of Federal
Regulations 1301.34(a), this is notice
that on April 29, 2013, GE Healthcare,
3350 North Ridge Avenue, Arlington
Heights, Illinois 60004–1412, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Cocaine
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
(9041), a basic class of controlled
substance listed in schedule II.
The company plans to import small
quantities of ioflupane, in the form of
three separate analogues of Cocaine, to
validate production and quality control
systems, for a reference standard, and
for producing material for a future
investigational new drug (IND)
submission.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedules I and II, which falls
under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR § 1301.43, and in such form
as prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 18, 2013.
This procedure is to be conducted
simultaneously with, and independent
E:\FR\FM\18JNN1.SGM
18JNN1
Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic classes of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–14456 Filed 6–17–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration,
National Center for Natural Products
Research-NIDA; Correction
In Federal Register (FR DOC) 2013–
09325 on page 23597, in the issue of
Friday, April 19, 2013, make the
following correction:
On page 23597, in the first column, in
the table, the last cells, ‘‘II’’ should read
‘‘I’’.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–14442 Filed 6–17–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
mstockstill on DSK4VPTVN1PROD with NOTICES
[OMB Number 1121–0277]
Agency Information Collection
Activities; Proposed Collection;
Comments Requested; Revisions of
Currently Approved Collection and
Extension of Currently Approved
Collection: OJJDP National Training
and Technical Assistance Center
(NTTAC) Evaluation Feedback Form
Package
ACTION:
Overview of This Information
Collection
30-Day Notice.
The Department of Justice, Office of
Justice Programs will be submitting the
VerDate Mar<15>2010
16:52 Jun 17, 2013
Jkt 229001
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published in the Federal Register
Volume 78, Number 52, page 16710 on
March 18, 2013, allowing for a 60-day
comment period.
The purpose of this notice is to allow
for an additional 30 days for public
comment until July 18, 2013. This
process is conducted in accordance with
5 CFR 1320.10.
Written comments and/or suggestions
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officers, Washington, DC 20503.
Additionally comments may be
submitted to OMB via facsimile to (202)
395–7285. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency/component,
including whether the information will
have practical utility;
(2) Evaluate the accuracy of the
agencies/components estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses.
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) The Title of the Form/Collection:
OJJDP NTTAC Evaluation Feedback
Form Package.
(3) The Agency form number, if any,
and the applicable component of the
Department of Justice sponsoring the
collection: Office of Juvenile Justice and
PO 00000
Frm 00090
Fmt 4703
Sfmt 9990
36595
Delinquency Prevention, Office of
Justice Programs, Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract. Primary: State, Local, or Tribal.
Other: Federal Government, Individuals
or households; Not-for-profit
institutions; Businesses or other forprofit. The Office for Juvenile Justice
and Delinquency Prevention National
Training and Technical Assistance
Center (NTTAC) Evaluation Feedback
Form Package is designed to collect inperson and online data necessary to
continuously assess the outcomes of the
assistance provided for both monitoring
and accountability purposes and for
continuously assessing and meeting the
needs of the field. OJJDP NTTAC will
send these forms to technical assistance
(TA) recipients; conference attendees;
training and TA providers; online
meeting participants; in-person meeting
participants; and focus group
participants to capture important
feedback on the recipients’ satisfaction
with the quality, efficiency, referrals,
information and resources provided and
assess the recipients’ additional training
and TA needs. The data will then be
used to advise NTTAC on ways to
improve the support provided to its
users; the juvenile justice field at-large;
and ultimately improve services and
outcomes for youth.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that 5140
respondents will complete forms and
the response time will range from .03
hours to 1.5 hours.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated
470.83 total annual burden hours
associated with this collection.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, U.S. Department of
Justice, Planning and Policy Staff,
Justice Management Division, 145 N
Street NE., Room 1407B, Washington,
DC 20530.
Dated: June 12, 2013.
Jerri Murray,
Department Deputy Clearance Officer, United
States Department of Justice.
[FR Doc. 2013–14355 Filed 6–17–13; 8:45 am]
BILLING CODE 4410–18–P
E:\FR\FM\18JNN1.SGM
18JNN1
]]>Agencies
[Federal Register Volume 78, Number 117 (Tuesday, June 18, 2013)]
[Notices]
[Pages 36594-36595]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14456]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application GE
Healthcare
Pursuant to Title 21, Code of Federal Regulations 1301.34(a), this
is notice that on April 29, 2013, GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois 60004-1412, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Cocaine (9041), a basic class of controlled substance
listed in schedule II.
The company plans to import small quantities of ioflupane, in the
form of three separate analogues of Cocaine, to validate production and
quality control systems, for a reference standard, and for producing
material for a future investigational new drug (IND) submission.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance listed in schedules I and II, which falls under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR Sec. 1301.43, and in such form as prescribed by 21
CFR Sec. 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 18, 2013.
This procedure is to be conducted simultaneously with, and
independent
[[Page 36595]]
of, the procedures described in 21 CFR Sec. 1301.34(b), (c), (d), (e),
and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, 40 FR 43745-46, all applicants for
registration to import a basic classes of any controlled substances in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
Sec. 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-14456 Filed 6-17-13; 8:45 am]
BILLING CODE 4410-09-P
